Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AXSM · as of Mar 31, 2025
Ownership Breakdown
379
Institutional Holders
▲ 53 vs Q4
$4.37B
Total Inst. Value
▲ $1.22B vs Q4
51.46M
Shares Outstanding
freeFloat 84.66%
37.44M
13F Shares Held
▲ 230,449 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AXSM largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 3.88M | 7.93% | 7.93% | $452.17B | May 9, 2025 | ▼ 25.5K |
BLACKROCK, INC. pharmaceutical preparations | 3.52M | 7.21% | 7.21% | $411.05B | May 2, 2025 | ▼ 9.0K |
RTW INVESTMENTS, LP pharmaceutical preparations | 2.92M | 5.98% | 5.98% | $340.88B | May 15, 2025 | ▼ 1.13M |
BVF INC/IL pharmaceutical preparations | 1.69M | 3.46% | 3.46% | $197.13B | May 15, 2025 | ▲ 302.2K |
FMR LLC pharmaceutical preparations | 1.25M | 2.55% | 2.55% | $145.46B | May 12, 2025 | ▲ 246.8K |
MACQUARIE GROUP LTD pharmaceutical preparations | 976.3K | 2.00% | 2.00% | $113.86B | Aug 14, 2025 | ▲ 12.2K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 934.9K | 1.91% | 1.91% | $109.06B | May 13, 2025 | ▲ 22.3K |
STATE STREET CORP pharmaceutical preparations | 906.0K | 1.85% | 1.85% | $105.67B | May 15, 2025 | ▼ 41.2K |
INVESCO LTD. pharmaceutical preparations | 857.0K | 1.75% | 1.75% | $99.95B | May 12, 2025 | ▲ 164.5K |
FAIRMOUNT FUNDS MANAGEMENT LLC pharmaceutical preparations | 815.2K | 1.67% | 1.67% | $95.07B | May 15, 2025 | ▼ 653.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+4.56M shares6
New Positions
first time holders17
Decreased
−3.15M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.41M
+4.56M / −3.15M
Net new holders
+16
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AXSM insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
8
Buy transactions
9
Sell transactions
0.89
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Coleman Mark director | May 29, 2026 | Sale | 6,000 | $233.46 | $1.40M | 41.1K | Form 4 ↗ |
Coleman Mark director | Jun 1, 2026 | Sale | 6,000 | $230.30 | $1.38M | 35.1K | Form 4 ↗ |
Coleman Mark director | Jun 2, 2026 | Sale | 5,537 | $223.39 | $1.24M | 29.6K | Form 4 ↗ |
Jacobson Mark L. Chief Operating Officer | May 5, 2026 | Sale | 233 | $228.18 | $53.2K | 0 | Form 4 ↗ |
Jacobson Mark L. Chief Operating Officer | May 4, 2026 | Sale | 4,517 | $227.94 | $1.03M | 0 | Form 4 ↗ |
Jacobson Mark L. Chief Operating Officer | Apr 21, 2026 | Award | 8,669 | — | — | 8.7K | Form 4 ↗ |
TABUTEAU HERRIOT Chief Executive Officer | Apr 21, 2026 | Award | 24,081 | — | — | 24.1K | Form 4 ↗ |
Maizel Ari Chief Commercial Officer | Apr 22, 2026 | Sale | 7,500 | $182.42 | $1.37M | 0 | Form 4 ↗ |
Maizel Ari Chief Commercial Officer | Apr 21, 2026 | Award | 7,224 | — | — | 7.2K | Form 4 ↗ |
Pizzie Nick Chief Financial Officer | Apr 21, 2026 | Award | 8,188 | — | — | 8.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Axsome Therapeutics, Inc. (AXSM) is primarily owned by institutional investors, who hold approximately 72.8% of total shares outstanding. Company insiders own approximately 15.34%, while retail and public investors account for the remaining 11.90%.
The largest institutional shareholder of Axsome Therapeutics, Inc. is VANGUARD GROUP INC, holding approximately 3.88 million shares — equal to 7.93% of outstanding shares — as of March 31, 2025.
A total of 379 institutional investors currently hold AXSM stock, with a combined institutional value of approximately $4.37 billion as of the most recent 13F filing period.
Frequently asked questions
AXSM ownershipAxsome Therapeutics, Inc. (AXSM) is primarily owned by institutional investors, who hold approximately 72.8% of shares. The largest shareholder is VANGUARD GROUP INC with a 7.93% stake. Company insiders hold 15.34%. Data sourced from SEC Form 13F as of March 31, 2025.